Australia markets open in 5 hours 46 minutes

Immutep Limited (IMM.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.2750+0.0300 (+12.24%)
At close: 4:10PM AEDT
Full screen
Previous close0.2450
Open0.2450
Bid0.2700 x 0
Ask0.2650 x 0
Day's range0.2400 - 0.2750
52-week range0.1000 - 0.4950
Volume2,013,659
Avg. volume1,990,272
Market cap135.539M
Beta (5Y monthly)1.34
PE ratio (TTM)N/A
EPS (TTM)-0.0340
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.08
  • GlobeNewswire

    Immutep Granted European Patent for IMP761

    SYDNEY, Australia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 3344654) entitled “Anti-LAG-3 Antibodies” by the European Patent Office. The claims of the patent are directed to Immutep’s pre-clinical product candidate, IMP761, and also to the use of IMP761 in the treatment of T-cell mediated inflammatory and autoimmune diseases. The expiry date of the patent is 1 September 2036.Immutep CEO, Marc Voigt stated: “IMP761 is the first agonist antibody that targets the immune checkpoint LAG-3 and aims to treat the root cause of autoimmune diseases such as, for example, inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis. It is very pleasing to see the grant of this patent in the important European market which will underpin ongoing investment in this promising product candidate.”Immutep CSO and CMO, Dr. Frederic Triebel also stated: “There continues to be a significant unmet medical need for patients with various autoimmune diseases and so it is highly encouraging to see the recent progress being made with IMP761 towards clinical development, both in terms of cell line development announced in April 2020 and now with securing intellectual property protection.”About IMP761 IMP761 is a first-in-class immunosuppressive agonist antibody to LAG-3. As a targeted immunosuppressive antibody, IMP761 has the potential to address the root cause of autoimmune diseases by specifically silencing the autoimmune memory T cells accumulating at the disease site which express LAG-3 as an exhaustion marker after being repeatedly stimulated with dominant self-peptides.In April 2020, Immutep announced that its partner, Batavia Biosciences, had developed a pharmaceutical-grade, stable CHO cell line that produces significantly high product yields of IMP761. The Company will now complete the preparations for the Good Manufacturing Practice (GMP) process compliance development phase, ahead of commencement of clinical testing of the candidate in autoimmune disease.In addition, in early 2019 Immutep reported encouraging preclinical results from its studies with IMP761. The in vivo studies showed that IMP761 decreases inflammatory T cell infiltration induced by intra-dermal injection of an antigen. These findings were published in the Journal of Immunology in January 2020.Further information can be found on the Company’s website www.immutep.com or by contacting:Australian Investors/Media: Catherine Strong, Citadel-MAGNUS +61 (0)406 759 268; cstrong@citadelmagnus.comU.S. Media: Tim McCarthy, LifeSci Advisors +1 (212) 915.2564; tim@lifesciadvisors.com

  • GlobeNewswire

    Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020

    SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that interim Overall Survival (OS) results from its Phase IIb AIPAC study has been selected to be presented in a spotlight presentation at the San Antonio Breast Cancer Symposium 2020, which is being held virtually in December 2020 from Texas, USA. Details for the spotlight presentation:Abstract Title: Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients Session Date & Time: Friday, 11 December 2020 at 2:15 pm US CST / Saturday, 12 December 2020 at 7:15 am Australian EDTSession Title: Spotlight Poster Discussion 14The San Antonio Breast Cancer Symposium 2020 is a leading international conference focused on clinical, translational and basic research in breast cancer. It is attended by a broad international audience of academic and private researchers and physicians from over 90 countries.Immutep will make the poster presentation available on its website following its publication at the San Antonio Breast Cancer Symposium 2020.         About the AIPAC trial Active Immunotherapy PAClitaxel (AIPAC) is a Phase IIb clinical trial in HER2-negative/ HR positive metastatic breast cancer. Based on Immutep’s LAG-3 technology, the study evaluates the combination of the Company’s lead product candidate, eftilagimod alpha (efti, LAG-3Ig or IMP321), and a taxane chemotherapy, called paclitaxel. This combination is aimed at boosting the immune response against tumour cells compared to chemotherapy alone.In the AIPAC trial, 227 hormone receptor positive metastatic breast cancer patients were randomised 1:1 to treatment A (paclitaxel chemotherapy plus placebo) or treatment B (paclitaxel chemotherapy plus efti) for six months. Patients received weekly paclitaxel at Days 1, 8 and 15 with either efti or placebo injected subcutaneously, on Days 2 and 16 of each 4-week cycle, repeated for 6 cycles. Thereafter, patients passed over to the maintenance phase with efti alone.For more information regarding the AIPAC trial, visit clinicaltrials.gov (identifier NCT02614833) and https://www.ncbi.nlm.nih.gov/pubmed/30977393.About ImmutepFurther information can be found on the Company’s website www.immutep.com or by contacting:Australian Investors/Media: Catherine Strong, Citadel-MAGNUS +61 (0)406 759 268; cstrong@citadelmagnus.comU.S. Media: Tim McCarthy, LifeSci Advisors +1 (212) 915.2564; tim@lifesciadvisors.com

  • Need To Know: Immutep Limited (ASX:IMM) Insiders Have Been Buying Shares
    Simply Wall St.

    Need To Know: Immutep Limited (ASX:IMM) Insiders Have Been Buying Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...